Christian Tang. Axelsen

Christian Tang. Axelsen

Auto-generated profile, based on publicly available information

Christian Tang. Axelsen

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ILIben Lyskjær
Iben Lyskjær
LILaura Iisager
Laura Iisager
CAChristian Tang. Axelsen
Christian Tang. Axelsen
TNTommy Kjærgaard Nielsen
Tommy Kjærgaard Nielsen
LDLars Dyrskjøt
Lars Dyrskjøt
THTina Hedegaard
Tina Hedegaard
The incidence of renal cell carcinoma (RCC) is increasing worldwide, yet research within this field is lagging behind other cancers. Despite increased detection of early disease as a consequence of the widespread use of diagnostic CT scans, 25% of patients have disseminated disease at diagnosis. Similarly, around 25% progress to metastatic disease following curatively intended surgery. Surgery is the cornerstone in the treatment of RCC; however, when the disease is disseminated, immunotherapy or immunotherapy in combination with a tyrosine kinase inhibitor is the patient's best option. Immunotherapy is a potent treatment, with durable treatment responses and potential to cure the patient, but only half of the patients benefit from the administered treatment, and there are currently no methods that can identify which patients will respond to immunotherapy. Moreover, there is a need to identify the patients in greatest risk of relapsing after surgery for localized disease and direct adjuvant treatment there. Even though several molecular biomarkers have been published to date, we are still lacking routinely used biomarkers to guide optimal clinical management. The purpose of this review is to highlight some of the most promising biomarkers, discuss the efforts made within this field to date, and describe the barriers needed to be overcome to have reliable and robust predictive and prognostic biomarkers in the clinic for renal cancer.